EyePoint Pharmaceuticals (NSDQ:EYPT) said this week that the Centers for Medicare and Medicaid Services approved transitional pass-through status and reimbursement of its dexamethasone intraocular suspension, Dexycu.
The FDA-approved product is designed to treat inflammation following cataract surgery using a single, intraocular dose of long-acting dexamethasone.
Get the full story at our sister site, Drug Delivery Business News.
The post EyePoint nabs CMS reimbursement for Dexycu cataract surgery drug appeared first on MassDevice.